Background <p>Metabolites are closely linked to individual health and disease conditions. Identifying genetic factors influencing metabolite levels in specific diseases can enhance our understanding of disease etiology and informing precision medicine. This study aims to characterize the genetic architecture of metabolites in specific disease states and explore their potential biological functions.</p> Methods <p>We conducted a comprehensive genome-wide metabolite quantitative trait locus (metQTL) analysis of 249 plasma metabolites across 40 disease states, based on nuclear magnetic resonance (NMR) data. To predict the biological significance of metQTLs, we performed a systematic functional annotation encompassing the analysis of genomic positions, heritability assessment, histone and transcription factor (TF) enrichment, effector gene identification, and potential drug targets evaluation. Furthermore, Mendelian randomization (MR) analyses were applied to uncover causal metabolites associated with diseases, and polygenic risk score (PRS) models were constructed to assess their predictive capacity for disease outcomes.</p> Results <p>Across 40 common disease types, we identified 283,563 metQTL-metabolite association pairs involving 249 metabolites and 149,984 metQTLs derived from 26,536 independent loci. Functional annotations indicated that these metQTLs influence chromatin activity and transcription factor binding, suggesting their key roles in epigenetic regulation. Mendelian randomization analysis revealed 104 reliable causal evidence between metabolites and diseases. Additionally, metQTL-derived disease PRS models demonstrated excellent performance in the risk stratification of 8 diseases, offering a framework for translating genetic resources into clinical applications. An online platform, “metQTL-Atlas” (<a href="https://metqtl.whu.edu.cn/home">https://metqtl.whu.edu.cn/home</a>), has been established for convenient browsing and downloading of our comprehensive results.</p> Conclusions <p>This study provides a comprehensive resource that delineates the genetic architecture of metabolites across diverse disease contexts, offering new insights into disease etiology and advancing precision medicine through enhanced risk prediction and therapeutic target discovery.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Genetic atlas of plasma metabolome across 40 human common diseases: mapping causal metabolites to disease risk

  • Yanmin Li,
  • Yimin Cai,
  • Qianying Ma,
  • Xiaojun Yang,
  • Chunyi He,
  • Ying Xu,
  • Ming Zhang,
  • Zequn Lu,
  • Can Chen,
  • Caibo Ning,
  • Bo Liu,
  • Yongchang Wei,
  • Xiangpan Li,
  • Meng Jin,
  • Xu Zhu,
  • Bin Li,
  • Ying Zhu,
  • Chaoqun Huang,
  • Xiaoping Miao,
  • Jianbo Tian

摘要

Background

Metabolites are closely linked to individual health and disease conditions. Identifying genetic factors influencing metabolite levels in specific diseases can enhance our understanding of disease etiology and informing precision medicine. This study aims to characterize the genetic architecture of metabolites in specific disease states and explore their potential biological functions.

Methods

We conducted a comprehensive genome-wide metabolite quantitative trait locus (metQTL) analysis of 249 plasma metabolites across 40 disease states, based on nuclear magnetic resonance (NMR) data. To predict the biological significance of metQTLs, we performed a systematic functional annotation encompassing the analysis of genomic positions, heritability assessment, histone and transcription factor (TF) enrichment, effector gene identification, and potential drug targets evaluation. Furthermore, Mendelian randomization (MR) analyses were applied to uncover causal metabolites associated with diseases, and polygenic risk score (PRS) models were constructed to assess their predictive capacity for disease outcomes.

Results

Across 40 common disease types, we identified 283,563 metQTL-metabolite association pairs involving 249 metabolites and 149,984 metQTLs derived from 26,536 independent loci. Functional annotations indicated that these metQTLs influence chromatin activity and transcription factor binding, suggesting their key roles in epigenetic regulation. Mendelian randomization analysis revealed 104 reliable causal evidence between metabolites and diseases. Additionally, metQTL-derived disease PRS models demonstrated excellent performance in the risk stratification of 8 diseases, offering a framework for translating genetic resources into clinical applications. An online platform, “metQTL-Atlas” (https://metqtl.whu.edu.cn/home), has been established for convenient browsing and downloading of our comprehensive results.

Conclusions

This study provides a comprehensive resource that delineates the genetic architecture of metabolites across diverse disease contexts, offering new insights into disease etiology and advancing precision medicine through enhanced risk prediction and therapeutic target discovery.